on NEOVACS (EPA:ALNEV)
Capital reduction at Neovacs
On May 6, 2025, Neovacs, a biopharmaceutical company listed on Euronext Growth Paris, announced a reduction in its share capital. This decision results from the 13th resolution adopted at the General Meeting of June 27, 2024. The par value of the share decreased from €0.01 to €0.001. Consequently, Neovacs' share capital is reduced from €1,130,914.63 to €113,091.463.
The purpose of this reduction is to offset losses. This announcement is accompanied by a warning regarding financing in the form of OCEANE-BSA and ORA bonds, which may put pressure on the share price and lead to dilution. Investors are urged to exercise caution regarding these dilutive transactions.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all NEOVACS news